Ophthalmology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
The Sahlgrenska Centre for Pediatric Ophthalmology Research, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Br J Ophthalmol. 2023 Dec 18;108(1):137-142. doi: 10.1136/bjo-2022-322022.
To determine the ophthalmological outcome at 6.5 years of age in children treated for retinopathy of prematurity (ROP), and registered in the national Swedish National Register for ROP register.
Data on ROP, treatment and ophthalmological outcome were retrieved from the register. Visual acuity (VA), refractive errors and strabismus, together with visual impairment (VI) and any significant eye problem, defined as VA >0.5 logarithm of the minimal angle of resolution (logMAR) and/or strabismus and/or any refractive error were analysed. Risk factors such as sex, gestational age (GA), birth weight SD score, number of treatments and retreatments, postnatal age and postmenstrual age at first treatment were analysed.
Follow-up data were available in 232 of 270 children born between 2007 and 2014 who had been treated for ROP. VI (VA >0.5 logMAR) was found in 32 (14%), strabismus in 82 (38%), refractive errors in 114 (52%) and significant eye problem in 143 (65%) children. Retreatment was a risk factor for VI and refractive errors. Male sex and neonatal brain lesion were risk factors for strabismus. An additional week of GA at birth reduced the risk for refractive errors, strabismus and significant eye problems.
The results of the present study revealed a high number of eye problems in children treated for ROP, emphasising the need for long-term follow-up. Retreatment of ROP was a risk factor for VI, and emphasises the importance of an accurate first treatment for the long-term ophthalmological outcome.
确定在接受早产儿视网膜病变(ROP)治疗并在瑞典国家 ROP 登记处登记的儿童中,6.5 岁时的眼科结局。
从登记处检索 ROP、治疗和眼科结局的数据。分析视力(VA)、屈光不正和斜视以及视力障碍(VI)和任何显著眼部问题,定义为 VA >0.5 最小角分辨率对数(logMAR)和/或斜视和/或任何屈光不正。分析了性别、胎龄(GA)、出生体重标准差评分、治疗次数和再治疗次数、出生后年龄和首次治疗时的月经龄等风险因素。
2007 年至 2014 年间出生的 270 名接受 ROP 治疗的儿童中,有 232 名儿童的随访数据可用。32 名(14%)儿童有 VI(VA >0.5 logMAR),82 名(38%)儿童有斜视,114 名(52%)儿童有屈光不正,143 名(65%)儿童有显著眼部问题。再治疗是 VI 和屈光不正的危险因素。男性和新生儿脑损伤是斜视的危险因素。出生时增加一周的 GA 可降低屈光不正、斜视和显著眼部问题的风险。
本研究结果显示,接受 ROP 治疗的儿童存在大量眼部问题,强调需要长期随访。ROP 的再治疗是 VI 的危险因素,强调首次治疗准确对长期眼科结局的重要性。